Finding the right dose of zanubrutinib for new immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an oral medication called zanubrutinib to find the best dose for adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, leading to low counts and bleeding risk. It may offer a new treatment option for those who haven't had any prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with ITP and have not yet received any treatment for it.
- Your platelet count is below 30,000 per microliter of blood, or below 50,000 with significant bleeding like easy bruising or bleeding gums.
- You are not pregnant, nursing, or planning to become pregnant during the study.
- You do not have other major medical conditions like heart, lung, liver, or kidney disease, or active infections such as HIV or hepatitis.
- You have not taken certain drugs like chemotherapy or blood thinners in the last 6 months.
- You can sign a consent form and are willing to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
This trial tests a combination of upadacitinib (a pill that calms the immune system) and high-dose dexamethasone (a steroid) as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this mix can safely raise platelet counts better than steroids alone.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This trial tests a new drug called pirtobrutinib for people with immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it can help raise your platelet count and reduce bleeding risk.
This trial tests whether adding a drug called orelabrutinib to high-dose dexamethasone (a steroid) works better than dexamethasone alone for treating newly diagnosed immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing very low blood counts. The goal is to see if the combination helps raise your platelet count and prevents bleeding.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.